B. Metzler seel. Sohn & Co. AG Purchases New Stake in Madrigal Pharmaceuticals, Inc. $MDGL

B. Metzler seel. Sohn & Co. AG acquired a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,221 shares of the biopharmaceutical company’s stock, valued at approximately $560,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Mather Group LLC. bought a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter valued at about $33,000. Global Retirement Partners LLC lifted its holdings in Madrigal Pharmaceuticals by 221.7% in the third quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 51 shares during the last quarter. First Horizon Corp acquired a new position in Madrigal Pharmaceuticals in the third quarter valued at approximately $34,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter worth approximately $39,000. Finally, GAMMA Investing LLC raised its position in shares of Madrigal Pharmaceuticals by 114.3% during the 3rd quarter. GAMMA Investing LLC now owns 90 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 48 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insider Transactions at Madrigal Pharmaceuticals

In related news, Director Rebecca Taub sold 18,410 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $522.40, for a total transaction of $9,617,384.00. Following the transaction, the director owned 455,589 shares in the company, valued at $237,999,693.60. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mardi Dier sold 1,982 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $430.87, for a total value of $853,984.34. Following the sale, the chief financial officer directly owned 12,490 shares in the company, valued at approximately $5,381,566.30. The trade was a 13.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 55,612 shares of company stock worth $28,326,065 over the last ninety days. Insiders own 21.50% of the company’s stock.

Analysts Set New Price Targets

MDGL has been the subject of a number of analyst reports. Wolfe Research set a $579.00 price objective on Madrigal Pharmaceuticals in a research report on Tuesday, January 6th. Piper Sandler increased their target price on Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the stock an “overweight” rating in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, January 22nd. B. Riley Financial boosted their price target on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Canaccord Genuity Group upped their price target on shares of Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $685.31.

Madrigal Pharmaceuticals Stock Down 0.3%

Shares of Madrigal Pharmaceuticals stock opened at $431.53 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.01 and a quick ratio of 3.77. Madrigal Pharmaceuticals, Inc. has a 1-year low of $265.00 and a 1-year high of $615.00. The business’s fifty day moving average price is $483.48 and its two-hundred day moving average price is $488.06. The company has a market capitalization of $9.90 billion, a P/E ratio of -33.53 and a beta of -0.97.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The business had revenue of $321.08 million during the quarter, compared to the consensus estimate of $310.36 million. During the same period in the previous year, the company posted ($2.71) EPS. The company’s revenue for the quarter was up 210.8% compared to the same quarter last year. As a group, research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.